AK37: The first pyridoacridine described capable of stabilizing the topoisomerase I cleavable complex

Anti-Cancer Drugs

Volumn 15, Issue 9, 2004, Pages 907-913

  Marshall, Kathryn M ^a   Holden, Joseph A ^b   Koller, Avi ^c   Kashman, Yoel ^c   Copp, Brent R ^d   Barrows, Louis R ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

9 aminocamptothecin; AK37; Cleavable complex; Pyridoacridine; Topoisomerase I; Wakayin

Indexed keywords

9 AMINOCAMPTOTHECIN; ACRIDINE DERIVATIVE; AK 36; AK 37; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; UNCLASSIFIED DRUG; WAYAKIN;

ARTICLE; CANCER INHIBITION; CATALYSIS; COMPARATIVE STUDY; COMPLEX FORMATION; CONTROLLED STUDY; DNA CLEAVAGE; DRUG INHIBITION; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTERCALATION COMPLEX; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; ENZYME STABILITY; HUMANS; INTERCALATING AGENTS; PHENANTHROLINES;

EID: 8344262388     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200410000-00012     Document Type: Article

References (32)

1. Faulkner DJ. Marine natural products. Nat Prod Rep 2002; 19:1-48.
2. Harper MK, Bungi TS, Copp BR, James RD, Lindsay BS, Richardson AD, et al. Introduction to the chemical ecology of marine natural products. In: McClintock JB, Baker BJ (editors): Marine Chemical Ecology. Boca Raton, FL: CRC Press; 2001. pp. 3-69.
3. Ding Q, Chichak K, Lown JW. Pyrroloquinoline and pyridoacridine alkaloids from marine sources. Curr Med Chem 1999; 6:1-27.
4. 13C coupling constants. J Am Chem Soc 1983; 105:4835-4836.
5. Taraporewala IB, Cessac JW, Chanh TC, Delgado AV, Schinazi RF. HIV-1 neutralization and tumor cell proliferation inhibition in vitro by simplified analogues of pyrido[4,3,2-mn]thiazole[5,4-b]acridine marine alkaloids. J Med Chem 1992; 35:2744-2752.
6. McCarthy PJ, Pitts TP, Gunawardana GP, Kelly-Borges M, Pomponi SA. Antifungal activity of meridine, a natural product from the marine sponge Corticium sp. J Nat Prod 1992; 55:1664-1668.
7. Marshall KM, Matsumoto SS, Holden JA, Concepciün GP, Tasdemir D, Ireland CM, et al. The anti-neoplastic and novel topoisomerase II-mediated cytotoxicity of neoamphimedine, a marine pyridoacridine. Biochem Pharmacol 2003; 66:447-458.
8. Matsumoto SS, Sidford MH, Holden JA, Barrows LR, Copp BR. Mechanism of action studies of cytotoxic marine alkaloids: ascididemin exhibits thiol-dependent oxidative DNA cleavage. Tetrahedron Lett 2000; 41:1667-1670.
9. Matsumoto SS, Biggs J, Copp BR, Holden JA, Barrows LR. Mechanism of ascididemin-induced cytotoxicity. Chem Res Toxicol 2003; 16:113-122.
10. Kobayashi J, Cheng J, Wälchli MR, Nakamura H, Hirata Y, Sasaki T, et al. Cystodytins A, B, and C, novel tetracyclic aromatic alkaloids with potent antineoplastic activity from the Okinawan tunicate Cystodytes dellechiajei. J Org Chem 1988; 53:1800-1804.
11. Aoki S, Wei H, Matsui K, Rachmat R, Kobayashi M. Pyridoacridine alkaloids inducing neuronal differentiation in a neuroblastoma cell line, from marine sponge Biemna fortis. Bioorg Med Chem 2003; 11:1969-1973.
12. Molinski TF. Marine pyridoacridine alkaloids: structure, synthesis, and biological chemistry. Chem Rev 1993; 93:1825-1838.
13. Gunawardana GP, Koehn FE, Lee AY, Clardy J, He H, Faulkner DJ. Pyridoacridine alkaloids from deep-water marine sponges of the family Pachastrellidae: structure revision of dercitin and related compounds and correlation with the kuanoniamines. J Org Chem 1992; 57:1523-1526.
14. Tasdemir D, Marshall KM, Mangalindan GC, Concepciün GP, Barrows LR, Harper MK, et al. Deoxyamphimedine, a new pyridoacridine alkaloid from two tropical Xestospongia sponges. J Org Chem 2001; 66:3246-3248.
15. Lindsay BS, Barrows LR, Copp BR. Structural requirements for biological activity of the marine alkaloid ascididemin. Bioorg Med Chem Lett 1995; 5:739-742.
16. Wall ME, Wani MC. Camptothecin. Discovery to clinic. Ann NY Acad Sci 1996; 803:1-12.
17. Holden JA. DNA topoisomerases as anticancer drug targets: from the laboratory to clinic. Curr Med Chem Anticancer Agents 2001; 1:1-25.
18. Pommier Y. Diversity of DNA topoisomerases I and inhibitors. Biochimie 1998; 80:255-270.
19. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000; 7:39-58.
20. Kokoshka JM, Capson TL, Holden JA, Ireland CM, Barrows LR. Differences in the topoisomerase I cleavage complexes formed by camptothecin and wakayin, a DNA-intercalating marine natural product. Anticancer Drugs 1996; 7:758-765.
21. Koller A, Rudi A, Gravalos MG, Kashman Y. Synthesis and electrophilic substitution of pyrido[2,3,4-kl]-acridines. Molecules 2001; 6: 300-322.
22. Matsumoto SS, Haughey HM, Schmehl DM, Venables DA, Ireland CM, Holden JA, et al. Makaluvamines vary in ability to induce dose-dependent DNA cleavage via topoisomerase II interaction. Anticancer Drugs 1999; 10:39-45.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
24. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986; 89:271-277.
25. McDonald LA, Eldredge GS, Barrows LR, Ireland CM. Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II. J Med Chem 1994; 37: 3819-3827.
26. Ruddon RW. Chemical mutagenesis. In: Pratt WB, Taylor P (editors): Principles of Drug Action. Philadelphia, PA: Churchill Livingstone; 1990, pp. 691-733.
27. Holden JA. Purification of DNA topoisomerase I from human placenta. Methods Mol Biol 1999; 94:213-322.
28. Holden JA, Rolfson DH, Wittwer CT. Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry 1990; 29:2127-2134.
29. Holden JA, Rolfson DH, Wittwer CT. The distribution of immunoreactive topoisomerase II protein in human tissues and neoplasms. Oncol Res 1992; 4:157-166.
30. Barrows LR, Holden JA, Anderson M, D'Arpa P. The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication. Mutat Res 1998; 408: 103-110.
31. Jeggo PA, Caldecott K, Pidsley S, Banks GR, Sensitivity of Chinese hamster ovary mutants defective in DNA double strand break repair to topoisomerase II inhibitors. Cancer Res 1989; 49:7057-7063.
32. Holden JA, Wall ME, Wani MC, Manikumar G. Human DNA topoisomerase I: quantitative analysis of the effect of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage. Arch Biochem Biophys 1999; 370:66-76.